Contribute Try STAT+ Today

CytoDyn CEO Nader Pourhassan has been uncharacteristically quiet this week about a completed clinical trial involving patients with severe, life-threatening cases of Covid-19.

It’s uncharacteristic because Pourhassan has not been shy in touting the potential of CytoDyn’s only drug, an experimental antibody called leronlimab — not currently approved to treat anything. He has claimed leronlimab is capable of effectively treating HIV, 22 different types of cancer, fatty liver disease, multiple sclerosis, and Alzheimer’s disease, among other ailments. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.